About
Escalante is a San Francisco biotech combining molecular biology, protein biochemistry and AI/ML to build a platform for scalable, functional single-molecule proteomics, aiming to build AI models that predict how cells respond to therapeutic perturbations for drug discovery and diagnostics.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Escalante
Escalante is a San Francisco biotech combining molecular biology, protein biochemistry and AI/ML to build a platform for scalable, functional single-molecule proteomics, aiming to build AI models that predict how cells respond to therapeutic perturbations for drug discovery and diagnostics.
$7M
$7M
United States
BusinessLatest roundTotal raisedDate- RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M - Noetik
AI-based drug discovery, cancer immunology
Seed · $14M · 2023-09
$14M - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M
China
BusinessLatest roundTotal raisedDate- Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Miles Wang 新公司
Develops AI models for drug discovery
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.